Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 2/2007

01-06-2007 | Original paper

The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management

Authors: Vesna Bjegovic, Zorica Terzic, Jelena Marinkovic, Nebojsa Lalic, Sandra Sipetic, Ulrich Laaser

Published in: The European Journal of Health Economics | Issue 2/2007

Login to get access

Abstract

The purpose of this study was to analyse whether the nationwide application of the national Serbian guideline for diabetes mellitus (NSGDM) would save a relevant amount of disability-adjusted life years (DALYs) and/or reduce the medical cost of treating diabetic patients in Serbia, as compared to the present situation. Disability-adjusted life years were calculated for Serbia and the cost-effectiveness was analysed in eight population groups under ideal and present conditions; prevalent and incident cases were each split up for patients with blood glucose that was well controlled and that was uncontrolled. Under ideal conditions, i.e., according to the NSGDM, 8,031 DALYs could be saved with a potential cost reduction at the same time of approximately 19 million Euros. The implementation of the NSGDM in clinical practice bears a great potential to save lives and reduce years lived with lowered quality of life, but in addition it may reduce costs by about a quarter.
Literature
1.
Atanaskovic-Markovic, Z., Bjegovic, V., Jankovic, S., Kocev, N., Laaser, U., Marinkovic, J., Markovic-Denic, Lj., Pejin-Stokic Lj., Penev, g., Stanisavljevic, D., Santric-Milicevic, M., Saulic, A., Sipetic-Grujicic, S., Terzic-Supic, Z., Vlajinac, H.: The burden of disease and injury in Serbia. Ministry of Health, Belgrade (2003)
2.
National Committee for Guidelines of Clinical Practice in Serbia, Diabetes mellitus (chair: Professor N. Lalic): National Serbian Guideline for Diabetes Mellitus (NSGDM). The European Agency for Reconstruction/EPOS Health Consultants, Belgrade. Serbian version, Prevencija tipa 2 Dijabetesa (2005). Beograd (2002), ISBN 86-85313-36-8
3.
Murray, C.J.L., Lopez, A.D.: The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. The global burden of disease and injury series, vol 1. Harvard School of Public Health on Behalf of the World Health Organisation and The World Bank, Harvard University Press, Boston (1996)
4.
Statistical yearbook of Serbia and Montenegro. The Statistical Office, Belgrade (2003)
5.
Penev, G.: Mortality trends in Serbia during the 1990s. Stanovnistvo 41(1-4), 93–130 (2003)
6.
The Belgrade registry of diabetes mellitus. Institute of Public Health of Belgrade, Belgrade (2004)
7.
City Institute of Statistical Review of Health Services in Belgrade. City Institute of Public Health ,Belgrade (2000)
8.
Russell, B., Valiyeva, E., Roman, S.H., Pogach, L.M., Suh, D.C., Safford, M.M.: Hospitalizations, nursing home admissions, and deaths attributable to diabetes. Diabetes Care 28, 1611–1617 (2005)
9.
10.
Jönsson, B.: The economic impact of diabetes. Diabetes Care 21(Suppl. 3), C7–C10 (1998)
11.
King, H., Aubert, R.E., Herman, W.H.: Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21, 1414–1431 (1998)
12.
Schmitt-Koopmann, I., Schwenkglenks, M., Spinas, G.A., Szucs, T.D.: Direct medical costs of type 2 diabetes and its complications in Switzerland. Eur J Public Health 14, 3–9 (2004)
13.
Brandle, M., Burke, R., Zhou, H., Tabaei, B.P., Smith, B.R.K., Brown, M.B., Marriott, D.: The direct medical cost of type 2 diabetes. Diabetes Care 26, 2300–2304 (2003)
14.
The Diabetes Prevention Program Research Group.: Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 26, 36–47 (2003)
15.
Ragnarson, T.G., Apelqvist, J.: Prevention of diabetes-related foot-ulcers and amputations: a cost-utility analysis based on Markov model simulations. Diabetologia 44, 2077–2087 (2001)
16.
Ortegon, M.A., Redekop, W.K., Niessen, L.W.: Cost-effectiveness of prevention and treatment of the diabetic foot. Diabetes Care 27, 901–907 (2004)
17.
The CDC Diabetes Cost-effectiveness Group.: Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287, 2542–2551 (2002)
18.
The Diabetes Prevention Program Research Group.: Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 26, 2518–2523 (2003)
Metadata
Title
The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management
Authors
Vesna Bjegovic
Zorica Terzic
Jelena Marinkovic
Nebojsa Lalic
Sandra Sipetic
Ulrich Laaser
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 2/2007
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-006-0012-7

Other articles of this Issue 2/2007

The European Journal of Health Economics 2/2007 Go to the issue

Original paper

Pharmacoeconomic studies in Italy: a critical review of the literature

Discussion

Should we really worry about “launch delays” of new drugs in OECD countries? Reply to J Cohen

Original Paper

Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system

Pricing and Reimbursement Systems in Europe

Discussion point: should governments buy drug patents?

Editorial

The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience

Original paper

Systematic review of economic evaluations and cost analyses of guideline implementation strategies